R Squared’s Acadia Pharmaceuticals ACAD Stock Holding History

R Squared’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,560	Closed	-$47K	–	299
2024 Q4	$47K	Buy	+2,560	New	+$41.3K	0.05%	521

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

R Squared's ACAD Position: Q1 2025 in Review

R Squared sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 2,560 shares — an estimated $47K sold.

R Squared first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $47K in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

R Squared reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,560 Acadia Pharmaceuticals shares in Q1 2025, an estimated $47K.
R Squared first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Acadia Pharmaceuticals position peaked at $47K in Q4 2024.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.